Cardioprotective Effect of Apelin-13 on Cardiac Performance and Remodeling in End-Stage Heart Failure
-
- Koguchi Wataru
- Department of Hypertension and Cardiorenal Medicine, Dokkyo Medical University School of Medicine
-
- Kobayashi Naohiko
- Department of Hypertension and Cardiorenal Medicine, Dokkyo Medical University School of Medicine
-
- Takeshima Hiroshi
- Department of Hypertension and Cardiorenal Medicine, Dokkyo Medical University School of Medicine
-
- Ishikawa Mayuko
- Department of Hypertension and Cardiorenal Medicine, Dokkyo Medical University School of Medicine
-
- Sugiyama Fumihiro
- Department of Hypertension and Cardiorenal Medicine, Dokkyo Medical University School of Medicine
-
- Ishimitsu Toshihiko
- Department of Hypertension and Cardiorenal Medicine, Dokkyo Medical University School of Medicine
この論文をさがす
抄録
Background: Apelin and its cognate G protein-coupled receptor, APJ, constitute a signaling pathway with a positive inotropic effect on cardiac function. Recently, we and other investigators demonstrated that a reduction in myocardial apelin/APJ expression might play a critical role in experimental models of end-stage heart failure (HF). Therefore, we evaluated whether exogenous apelin infusion restores apelin/APJ expression and improves cardiac function in the failing heart of Dahl salt-sensitive hypertensive (DS) rats. Methods and Results: High salt-loaded DS rats were treated with vehicle and pyroglutamylated apelin-13 (Pyr-AP13; 200μg·kg-1·day-1, IP) from the age of 11 to 18 weeks. Decreased end-systolic elastance and percent fractional shortening in failing rats was significantly ameliorated by Pyr-AP13. Pyr-AP13 effectively inhibited vascular lesion formation and suppressed expression of inflammation factors such as tumor necrosis factor-α and interleukin-1β protein. Downregulation of apelin and APJ expression, and phosphorylation of endothelial nitric oxide synthase at Ser1177 and Akt at Ser473 in failing rats was significantly increased by Pyr-AP13. Upregulation of NAD(P)H oxidase p22phox, p47phox, and gp91phox in DS rats was significantly suppressed by Pyr-AP13. Conclusions: Exogenous apelin-13 may ameliorate cardiac dysfunction and remodeling and restore apelin/APJ expression in DS rats with end-stage HF. Thus, apelin-13 may have significant therapeutic potential for end-stage HF. (Circ J 2012; 76: 137-144)<br>
収録刊行物
-
- Circulation Journal
-
Circulation Journal 76 (1), 137-144, 2012
一般社団法人 日本循環器学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001205102617344
-
- NII論文ID
- 10030034426
-
- NII書誌ID
- AA11591968
-
- ISSN
- 13474820
- 13469843
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可